Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Event: Entry into a Material Definitive Agreement to acquire AZSTARYS®.
Key Financial Metrics and Transaction Terms
- Acquisition Target: AZSTARYS®, a CNS stimulant for ADHD treatment.
- Base Purchase Price: $650 million in cash, subject to customary adjustments.
- Potential Milestone Payments: Up to $135 million in aggregate cash contingent on regulatory and commercial milestones.
- Termination Fee: $24 million payable by Collegium under specified termination circumstances.
- Expected Closing: Second quarter of 2026.
- Financial Performance: The filing does not provide current revenue, profit, cash flow, or margin data for Collegium Pharmaceutical.
Material Changes and Strategic Impact
This filing represents a significant strategic expansion into the ADHD market. Collegium is acquiring the assets from Corium Therapeutics Holdings, LLC and Corium, LLC. The transaction involves the purchase of all issued and outstanding limited liability interests of GPC Commave Holding, LLC and a newly formed entity (NewCo). No prior period financial comparisons are included in this specific 8-K filing.
Guidance, Outlook, and Risks
Management Commentary: The acquisition is intended to bolster the Company's ADHD portfolio and commercial strategy. Management anticipates benefits from the integration of AZSTARYS, though specific projected revenue or EBITDA figures are not detailed in the text of this filing.
Risks and Contingencies:
- Regulatory Approval: Closing is subject to the expiration of Hart-Scott-Rodino Act waiting periods and other regulatory approvals.
- Transaction Completion: Risks include failure to close on proposed terms, integration challenges, and disruption to operations.
- Financial Uncertainty: Risks related to realizing anticipated benefits, unknown liabilities, and significant transaction costs.
- Market and Operational Risks: Includes competition, reimbursement challenges, supply chain constraints, and potential litigation (including opioid-related or patent infringement).
Investor Verification Checklist
- Verify the Company's current cash position and liquidity to fund the $650 million cash purchase.
- Review the full text of the Equity Purchase Agreement (Exhibit 2.1) for specific purchase price adjustment mechanisms.
- Monitor the status of Hart-Scott-Rodino Act waiting periods and other regulatory approvals required for closing.
- Assess the specific regulatory and commercial milestones required to trigger the $135 million in potential additional payments.
- Review the Company's most recent 10-K or 10-Q for detailed financial statements, as this 8-K does not contain historical financial data.